Benchmark raised shares of Emergent BioSolutions from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a report on Monday, April 10th.

Source: https://www.etfdailynews.com/2023/06/21/etf-managers-group-llc-cuts-holdings-in-emergent-biosolutions-inc-nyseebs/

Finally, Ancora Advisors LLC acquired a new stake in Emergent BioSolutions in the first quarter valued at approximately $66,000.

Source: https://www.americanbankingnews.com/2023/03/08/etf-managers-group-llc-sells-1160-shares-of-emergent-biosolutions-inc-nyseebs.html

Finally, Quantbot Technologies LP acquired a new position in Emergent BioSolutions in the first quarter valued at approximately $117,000.

Source: https://www.etfdailynews.com/2023/01/31/emergent-biosolutions-inc-nyseebs-stock-holdings-increased-by-barclays-plc/

NF2 BioSolutions UK and Europe is supporting a research project involving repurposing existing drugs for effective treatment.

Source: https://www.hexham-courant.co.uk/news/23694091.trio-walk-along-pennine-way-fundraising-challenge/?ref=rss

TheStreet downgraded Emergent BioSolutions from a “c-” rating to a “d” rating in a report on Monday, February 27th.

Source: https://www.etfdailynews.com/2023/06/02/emergent-biosolutions-inc-nyseebs-shares-purchased-by-first-trust-advisors-lp/